New schizophrenia cases in Ontario, Canada have nearly tripled since cannabis was legalised in 2015, according to a ...

A new study from Canadian researchers has found that the proportion of new schizophrenia cases associated with cannabis use ...

Resilience factors were associated with less severe positive and negative schizophrenia symptoms, suggesting resilience may play a protective role.

Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...

Potent cannabis linked to surging schizophrenia cases - New schizophrenia cases linked to cannabis use disorder more than doubled in Ontario after legalisation of drug ...

Schizophrenia and major depressive disorder (MDD) may be genetically associated with increased risk for constipation but only the latter association appears to be clinically significant, according to ...

In people with treatment-resistant depression, investigational inhalable mebufotenin yielded a 15.5-point placebo-adjusted ...

Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of marijuana, ...

The proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...

Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of ma ...

CNW/ - Holder of an innovative diagnostic support technology, recognized by the Food and Drug Administration (FDA) as a major scientific breakthrough, diaMentis unveils unprecedented results ...